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Nitric oxide (NO) is known to depress ribosomebiogenesis in vitro. In this studywe analyzed
the inﬂuence of exogenous NO on ribosome biogenesis in vivo using a proven antihyper-
tensivemodel of perinatal NO administration in genetically hypertensive rats. Fawn-hooded
hypertensive rat (FHH) dams were supplied with the NO-donor molsidomine in drinking
water from 2weeks before to 4weeks after birth, and the kidneys were subsequently
collected from 2day, 2week, and 9 to 10-month-old adult offspring. Although the NO-
donor increased maternal NO metabolite excretion, the NO status of juvenile renal (and
liver) tissue was unchanged as assayed by EPR spectroscopy of NO trapped with iron-
dithiocarbamate complexes. Nevertheless, microarray analysis revealedmarked differential
up-regulation of renal ribosomal protein genes at 2 days and down-regulation at 2weeks
and in adult males. Such differential regulation of renal ribosomal protein genes was not
observed in females. These changes were conﬁrmed in males at 2weeks by expression
analysis of renal ribosomal protein L36a and by polysome proﬁling, which also revealed
a down-regulation of ribosomes in females at that age. However, renal polysome proﬁles
returned to normal in adults after early exposure to molsidomine. No direct effects of mol-
sidomine were observed on cellular proliferation in kidneys at any age, and the changes
induced by molsidomine in renal polysome proﬁles at 2weeks were absent in the livers of
the same rats. Our results suggest that the previously found prolonged antihypertensive
effects of perinatal NO administrationmay be due to epigenetically programmed alterations
in renal ribosome biogenesis during a critical fetal period of renal development, and provide
a salient example of a drug-induced reduction of ribosome biogenesis that is accompanied
by a beneﬁcial long-term health effect in both males and females.
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INTRODUCTION
Plasticity of organogenesis provides an opportunity for interven-
tions in a speciﬁc window of early development that may have
long-term beneﬁcial or detrimental effects on adult health and
disease (McMillen and Robinson, 2005). One critical regulation
of such plasticity is protein synthesis. Upstream factors affect-
ing protein synthesis include tight regulations at multiple stages
of ribosome biogenesis. For example, it is well known that epige-
netic silencing of ribosomalDNA (rDNA) regularly occurs, even in
proliferating cells (McStay and Grummt, 2008; Sanij and Hannan,
2009). One exogenous factor that has been shown to affect rDNA
and ribosome biogenesis is nitric oxide (NO). Exposure of cells to
high levels of NO, using either NO-donors, or inducing expression
Abbreviations: FHH, fawn-hooded hypertensive rat; NO, nitric oxide.
of inducible NO synthase (iNOS), results in inhibition of the 80S
ribosomal complex (Kimet al., 1998) and enhanced rRNAcleavage
resulting in a reduction of both 60S and 80S ribosomal particles
(Cai et al., 2000).
Hypertension is associated with decreased NO availability
(Wilcox, 2005). The fawn-hooded hypertensive rat (FHH) is a
genetic model of hypertension susceptible to progressive renal
injury. In FHH hypertension is aggravated and the development
of renal injury is accelerated when NOS is chronically inhibited,
revealing partial NO dependency of the adult FHH phenotype
(Van Dokkum et al., 1998). Renal transplantation under different
conditions has shown that blood pressure regulation is intricately
linked to the kidney (Smallegange et al., 2004;Crowley et al., 2005),
and we hypothesized that this is also the case in the perinatal phase
(Koeners et al., 2008a). Recently, we observed that perinatal sup-
plementation of FHH dams with molsidomine, an NO-releasing
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prodrug (Feelisch, 1998; Singh et al., 1999), persistently lowered
the blood pressure and attenuated the development of renal injury
in male and female FHH (Koeners et al., 2008b).
Long-term regulation of blood pressure is determined by the
relationship between renal perfusion pressure and NaCl excre-
tion, and this relationship is facilitated by renal NO availability
(Cowley, 2008; Garvin et al., 2011). Thus our interest is directed
at mechanisms in the kidney that link availability of NO in early
development to regulation blood pressure in adult life. Conceiv-
ably temporal changes in the regulation of renal protein synthesis
via ribosomal control of gene translation could constitute such
a link (Kasinath et al., 2006). For instance, compensatory renal
hypertrophy involves a global increase in polysome proﬁles within
less than 1 day after uninephrectomy (Chen et al., 2005). Based
on the known effects of high levels of NO on the ribosomal ele-
ments in cultured cells, we hypothesized that ribosome biogenesis
in vivo in the neonatal FHH kidney may also be regulated by NO
availability. This perinatal regulation of ribosome biogenesis may
then affect kidney organogenesis in a manner that impacts the
long-term regulation of blood pressure and renal integrity.
Here we demonstrate that the perinatal administration of NO
results in a dramatic biphasic change of ribosomal protein gene
expression in FHH rats at 2 days and 2 weeks of age. This results in
decreased post-translational levels of certain ribosomal proteins,
and a remarkable reduction of assembled ribosome structures
at the 2-week point. Intriguingly, we did not ﬁnd an increase
in renal NO content at 2 weeks in the offspring of NO-donor-
treated rats. Our results suggest that the increased availability
of NO in gestation epigenetically alters renal ribosome biogen-
esis during a critical period of renal development. In conjunction
with previously published ﬁndings, we conclude that this effect by
NO may alter renal organogenesis in a manner that alleviates the
hypertension phenotype normally experienced by FHH rats.
MATERIALS AND METHODS
ANIMAL EXPERIMENT
Fawn-hooded hypertensive rat were from our own colony, derived
from the original colony at Erasmus University Rotterdam
(FHH/EUR) maintained by Dr. A. Provoost. FHH dams were
supplied with molsidomine (Sigma-Aldrich, Zwijndrecht,Nether-
lands) in drinkingwater (120 mg/L) 2 weeks before to 4 weeks after
birth. Control FHH mothers and their offspring received regular
tap water. All offspring from 4 weeks of age received regular tap
water and regular chow (Special Diets Services, Witham, Essex,
England). Offspring were sacriﬁced at 2 days, 2 weeks, 36 weeks
(males), and 42 weeks (females). The adult ages were chosen when
renal injury inmales and femaleswas similar.Kidneyswere isolated
and snap-frozen (for microarray analysis), kept on ice (for West-
ern blotting and polysome proﬁling), or ﬁxed in formaldehyde (for
immunohistochemistry). Note that although functional and mor-
phological data from the adult rats have been published previously
(Koeners et al., 2008b), all microarray data and all data pertaining
to renal ribosomal proteins in adult kidneys is novel. Directly after
weaningof thepups, the damswere placed inmetabolic cageswith-
out food but with access to water with 2% glucose and 24-h urine
was collected on antibiotic/antimycotic solution (Sigma-Aldrich)
to prevent degradation of NO metabolites. NO metabolites were
determined as described (Bongartz et al., 2010). Sentinel animals
were housed under the same conditions and regularly monitored
for infections by nematodes, pathogenic bacteria, and antibodies
for rodent viral pathogens (International Council for Laboratory
Animal Science, Nijmegen, Netherlands). The Utrecht University
Board for studies in experimental animals approved the protocol.
MICROARRAY
For an overview and extensive explanation of microarray data
processing, please see Appendix. In short, a piece of snap-frozen
kidney was put in 1 mL TRIzol (Invitrogen, Breda, Netherlands)
containing 100–150 mg 1 mm glass beads (BioSpec Products,
Bartlesville,OK,USA) and immediately homogenized in 30 s using
a mini-beadbeater (BioSpec). The total RNA was isolated accord-
ing to the manufacturer’s instructions. Total RNA was puriﬁed
using NucleoSpin RNA II kit (Macherey-Nagel,Düren,Germany).
Samples were then put on Illumina BeadChips (RatRef-12) by
ServiceXS1 (Leiden, Netherlands). Kidneys from 2 days, 2 weeks,
and adult FHH of both genders were used (at least n = 5/group).
All samples were randomly placed on different arrays in order to
minimize variation between BeadChips and between arrays.
After calculating the average intensity per probe, all arrays
were Log2-transformed and Quantile normalized. The arrays were
grouped and the average intensity was calculated. The signiﬁcance
of the differences in intensity between the groups was calculated
using Cyber t -test. This ﬁnal data containing normalized data,
average intensity per group and statistical signiﬁcance between
groups were used in data evaluation. The data are submitted as
MIAME-complaint to GEO2 under accession number GSE27725.
The number of genes differentially expressed in the mol-
sidomine samples were counted per age in each gender. These
were then compared in order to elucidate whether there were genes
persistently affected by molsidomine. The 40 genes that were most
differentially regulated (20 up and 20 down) by molsidomine were
collected at each age for each gender.
All genes encoding for ribosomal proteins were collected. The
differentially expressed genes encoding for ribosomal proteins
were compared at each age. In order to determine whether the
effect of molsidomine on ribosomal genes was stronger than on
general gene expression proﬁles, the ratio of differentially regu-
lated ribosomal genes to the whole ribosomal gene population
was compared to the ratio of total differentially expressed genes
with whole microarray data in a size test.
WESTERN BLOT ANALYSIS
Fresh kidney samples were lysed on ice in lysis buffer (50 mM
Tris–HCl pH7.5, 150 mMNaCl, 2 mMEDTA,1%TritonX-100; all
fromSigma-Aldrich) plus protease inhibitors (Santa Cruz Biotech,
#29130) and subjected to centrifugation at 14K rpm at 4˚C for
10 min. Protein content in the supernatants was quantiﬁed using
Biorad Protein Assay. 6× Laemmli loading buffer was added to
50μg samples which were then boiled for 5 min and loaded on a
10% SDS/PAGE gel. Transfers to PVDF membranes (Millipore,
#IPVH00010) were done overnight at 15V at 4˚C, blocked in
1www.servicexs.com
2http://www.ncbi.nlm.nih.gov/geo/
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5% milk/TBST solution for 1 h at RT, and subjected to blotting
with αL36a (Abnova, #H00006173-M02) or α-actin (Santa Cruz
Biotech, #1616) at dilutions of 1:200 in blocking buffer overnight
at 4˚C. Either α-mouse (L36a) or α-rabbit (actin) HRP-conjugated
secondary antibodies (GE Healthcare, #NXA931 and NA934) were
used at a dilution of 1:5000 in TBST for 20 min at RT. Blots were
washed 3× in TBST for 10 min at RT. Detection was done with
the ECL Advance Western Blot Detection Kit (GE Healthcare,
#RPN2135). Quantiﬁcations were performed using a GS-800 den-
sitometer (Biorad, Veenendaal, Netherlands) and Quantity One
software (Biorad).
POLYSOME PROFILING
The kidneys from FHH pups from control dams or dams treated
with molsidomine were collected at age 2 days and 2 weeks, main-
tained fresh on ice, and processed for polysome proﬁling on
the same day. For polysome proﬁling of adult tissue frozen kid-
ney tissue was used. Comparisons were only performed between
treated and control rats of both genders at each age. Livers from
2-week-old pups were used to determine tissue-speciﬁcity.
All steps of this protocol were performed at 4˚C or on ice.
Gradients of 17–50% sucrose (11 ml) in gradient buffer (110 mM
KAc, 20 mM MgAc2, and 10 mM HEPES pH 7.6) were prepared on
the day prior to use. Kidneys were lysed in 500μl polysome lysis
buffer (gradient buffer containing 100 mM KCl, 10 mM MgCl2,
0.1% NP-40, 2 mM DTT, and 40 U/ml RNasin; Promega, Leiden,
Netherlands) using a dounce homogenizer. The samples were cen-
trifuged at 1200 g for 10 min to remove debris and loaded onto
sucrose gradients. The gradients were ultracentrifuged for 2 h at
40,000 rpm in an SW41Ti rotor (Beckman-Coulter, USA). The
gradients were displaced into a UA6 absorbance reader (Tele-
dyne ISCO, USA) using a syringe pump (Brandel, USA) con-
taining 60% sucrose. Absorbance was recorded at an OD of
254 nm. All chemicals came from Sigma-Aldrich unless stated
otherwise.
TISSUE NO CONTENT
Endogenous NO levels in kidney and liver tissues of FHH
pups were assayed at 2 weeks by NO trapping with iron-
dithiocarbamate (Fe-DETC) complexes, as previously described
(Koeners et al., 2007; Van Faassen et al., 2008). Brieﬂy, the yields
of paramagneticNO-Fe(II)-DETC complexes (mononitrosyl-iron
complexes, MNIC) in tissues was quantiﬁed with EPR spec-
troscopy of intact frozen tissue sections at 77K. The tissues
were reduced at room temperature with dithionite (50 mM for
15 min) to remove the overlapping EPR signal from paramag-
netic Cu(II)-DETC complexes as commonly found in biological
materials.
IMMUNOHISTOCHEMISTRY
Kidneys were ﬁxed overnight at room temperature in 4%
formaldehyde. The tissue was embedded in parafﬁn and 4μm
sections were made on silanized glass slides. The slides were baked
at 58˚C overnight, deparafﬁnated, and rehydrated. Endogenous
peroxidase was blocked using citric acid. For antigen retrieval,
the sections were boiled for 20 min in citrate buffer (pH 6) and
allowed to cool slowly. The sections were then blocked in 1% BSA
(w/v) in PBS and incubated with rabbit-anti-pH3 (Santa Cruz
Biotech,#1791) overnight at 4˚C. The sectionswere then incubated
in anti-rabbit Powervision PO (Immunologic, #DPVR110 HRP)
for 30 min at RT and developed using DAB. Finally the sections
were counterstained in hematoxylin, dehydrated, and enclosed in
pertex. The quantiﬁcation was performed as follows: At 20× mag-
niﬁcation random ﬁelds were chosen, taking care not to include
the edges of the tissue. The number of positive cells was counted
in three ﬁelds of two sections per kidney. The average of these six
counts was used for analysis.
STATISTICS
For statistics in microarray, please refer to the methodology. For
other measurements the values are expressed as means± SEM.
Data were compared with unpaired t -test, one-way ANOVA, and
two-way ANOVA where appropriate followed by post hoc test
Student-Newman–Keuls. P < 0.05 is considered signiﬁcant.
RESULTS
BIOMETRICAL DATA
Biometrical data of FHH offspring and the number of rats studied
are collected in Table 1. Note that adult kidney weight and tail-cuff
blood pressure data, which were published previously (Koeners
et al., 2008b), are included in the table for the sake of convenience.
Molsidomine treatment decreased the kidney weight relative to
body weight in 2-day-old females (P < 0.05) but not at older ages.
However, in both male and female 2-week-old FHH rats rela-
tive kidney weight was unchanged. The kidneys of adult males
exposed to perinatal molsidomine weighed less than controls,
probably in associationwith reduced injury (Koeners et al., 2008b).
Perinatal molsidomine decreased systolic blood pressure in adult
FHH offspring (Koeners et al., 2008b). NO metabolites were
determined in a 24-h collection of urine from FHH dams to sub-
stantiate the direct effects of molsidomine in their pups. Indeed,
maternal urine NOx was increased by molsidomine (n = 4) vs.
controls (n = 4) from 1.6± 0.1 to 2.6± 0.2μmol/(100 g BW)/d
(P < 0.01).
TISSUE NO CONTENT
Although the NO-donor increased maternal NO metabolite excre-
tion, the NO status of 2-week-old renal (and liver) tissue was
unchanged as assayed by EPR spectroscopy of NO trapped with
iron-dithiocarbamate complexes (Table 2). Unfortunately, the NO
trapping procedure is not possible in 2-day-old pups.
MICROARRAY
Perinatal treatment with molsidomine signiﬁcantly affected tran-
scription of hundreds of genes at 2 days and at older ages (see
Figure A1 in Appendix). The data also clearly shows that the tran-
scriptional effect of molsidomine differs between ages. Few genes
remained differentially expressed at all ages and those that did
displayed bidirectional expression between ages.
The 40 most differentially expressed genes (20 induced and 20
reduced) were nearly all different between males and females at
the same age. Several genes encoding for ribosomal proteins were
present in the top 20 genes in males at all ages, however were less
present in the top 20 of females (see Tables A1A–F in Appendix).
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Table 1 | Biometrical data of control FHH and FHH during molsidomine (2days and 2weeks) or after perinatal molsidomine (adult).
Males Females
Controls Molsidomine Controls Molsidomine
2 DAYS
Number of pups/number of litters 12/7 12/7 12/6 19/10
RKW/BW (mg/g) 4.9±0.1 4.8±0.1 5.3±0.1 4.9±0.1#
2WEEKS
Number/litters 15/8 17/10 13/8 18/10
RKW/BW (mg/g) 5.2±0.1 5.3±0.1 5.3±0.1 5.5±0.1
ADULT
Number/litters 23/10 13/4 24/10 16/5
RKW/BW (mg/g) 3.8±0.1 3.4±0.03# 4.4±0.1 4.3±0.1
Systolic blood pressure (mmHg) 158±3 139±4# 145±5 118±5#
#P<0.05 vs. controls of same gender. Biometrical data in adults published previously (Koeners et al., 2008b) are included for the sake of convenience.
Table 2 | Nitric oxide yields (pmol MNIC/mg tissue) determined by EPR in kidneys and liver in of 2-week-old control FHH and 2-week-old FHH
offspring of dams treated with molsidomine.
Males Females
Controls Molsidomine Controls Molsidomine
2WEEKS
Number/litters 4/2 7/4 4/2 8/4
NO yield in kidney (left and right) 0.49±0.03 0.53±0.01 0.50±0.04 0.49±0.02
NO yield in liver 1.30±0.08 1.39±0.04 1.35±0.08 1.32±0.04
MNIC, mononitrosyl-iron complexes.
FIGURE 1 | Number of ribosomal protein genes that are differentially
expressed by molsidomine at each age per gender.The distribution of
these genes between ages per gender is shown in the Venn diagram. Below
the diagram is noted the total number of ribosomal protein genes that are
signiﬁcantly differentially expressed in molsidomine vs. control FHH rats at
each age.
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FIGURE 2 | Ribosomal protein genes in kidneys of FHH males
differentially expressed by molsidomine at 2weeks and whether these
genes were also regulated at other ages. All genes that are signiﬁcantly
differentially expressed by molsidomine at 2weeks are ranked (middle
panel). Some of these genes were also regulated at 2 days (upper panel) and
in adults (lower panel). The ratio of the genes is expressed as Log2(FM/FC),
where FM and FC are the normalized intensities of gene expression in the
molsidomine and control groups, respectively. Signiﬁcant differential
expression is indicated by a closed bar, non-signiﬁcant differential expression
by an open bar.
The present study is focused on the changes in ribosomal pro-
tein gene expression. Remarkably, these ribosomal protein genes
in males were differentially induced by molsidomine at 2 days,
then differentially reduced by molsidomine at both 2 weeks and in
adults (see Figures 1 and 2; the collection of genes are shown in
Table A2 in Appendix). These changes in ribosomal protein gene
expression were signiﬁcant at all ages (P < 0.05) and this effect
was speciﬁc for ribosomal genes only in males (vs. all genes in the
microarray; P < 0.001).
PROTEIN EXPRESSION OF L36a
In order to determine if the changes in ribosomal protein gene
expression suggested by the microarray analysis could be veri-
ﬁed at the protein level, we analyzed the expression of ribosomal
protein L36a at 2 days and 2 weeks. Table A2 in Appendix shows
that genes coding for the ribosomal protein L36a are subject to
some of the most signiﬁcant up-regulation at 2 days and down-
regulation at 2 weeks (and in adults) in molsidomine-treated FHH
males. Note that more than one ribosomal protein L36a gene from
different chromosomes is listed on Table 2. Western blot analysis
of kidney samples of FHH rats demonstrated that ribosomal pro-
tein L36a protein tends to be down-regulated by molsidomine
in 2 week males (Figure 3). Quantiﬁcation of three indepen-
dent experiments veriﬁed that this change in ribosomal protein
L36a protein expression occurred only in molsidomine-treated
males at 2 weeks (Figure 3). These results suggest that despite the
increase in ribosomal protein gene expression seen in 2-day-old
molsidomine-treated FHH males, this increases does not manifest
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FIGURE 3 |Western Blot on ribosomal protein L36a.Western blot
analysis was performed on kidneys lysates from 2day and 2week control
and molsidomine FHH rats of both genders using an antibody against
ribosomal protein L36a (upper panel). The measured band intensity of
ribosomal protein L36a was normalized by α-actin of the same sample
(ribosomal protein L36a/actin). The molsidomine effect on ribosomal protein
L36a/actin is expressed relative to the age- and gender matched control,
shown in graph by the dotted line (lower panel). The reduction in 2week
molsidomine males is borderline signiﬁcant (P =0.1). All 3 replicates are
biological.
as an increase in ribosomal protein levels (see also Figure 4). In
contrast, the western blot results suggest that the decrease in ribo-
somal protein gene expression at 2 weeks in molsidomine-treated
rats indeed does affect L36a proteins levels, as also supported by
the proﬁles of Figure 4.
RIBOSOMAL EVALUATION
Polysome proﬁling was performed on kidneys and the effects on
the peaks representing the small ribosomal subunit (40S), large
ribosomal subunit (60S), and monosome (80S) were determined
(Figure 4). Two days after birth and in adults,molsidomine had no
effect on polysome proﬁles, but 2 weeks after birth all peaks were
signiﬁcantly reduced by molsidomine in both males and females
(P < 0.01). This effect may be speciﬁc to the kidney, as no effect
of molsidomine was observed in males at 2 weeks of age in liver
polysome proﬁles (Figure 5). Northern blottingwas performed on
total RNA from 2 week FHH kidneys in order to determine rates
of rRNA processing (Figure A2 in Appendix). However, no differ-
ences were observed in processing using probes binding to either
the external transcribed spacer (ETS) or the internal transcribed
spacer 1 (ITS1).
IMMUNOHISTOCHEMISTRY
In order to determine if molsidomine resulted in a mitotic index
change, we subjected kidneys from FHH rats to staining with a
phospho-speciﬁc histone-3 (pH3) antibody (Figure 6).We saw no
difference in the number of pH3-positive cells on molsidomine-
treated FHH rat kidney slices compared to controls. As expected
the number of pH3-positive cells decreased as the age of the rats
increased. No pH3-positive cells were observed in adults (data not
shown).
DISCUSSION
Nitric oxide donors are known to inhibit proliferation of mesan-
gial and other glomerular cells in vitro (Rupprecht et al., 2000).
Little is known about the effects of NO-donors on early growth
and nephrogenesis. Recently we observed that administration of
NO-donors during early development ameliorates the long-term
phenotype in the FHH rat model of progressive hypertension-
linked renal injury (Koeners et al., 2008b).Assuming that the direct
effects of the NO-donor in early development were related to an
as of yet undeﬁned aspect of renal development, the present study
focused on a global analysis of ribosomal proteins as a key step in
the post-transcriptional regulation of protein synthesis.
The prominent presence of ribosomal protein genes, especially
in FHH males, on the lists of the most differentially expressed
genes as a result of perinatal NO administration led us to examine
how these changes in gene expression affected the protein levels of
an individual ribosomal protein as well as the structures of mature,
assembled ribosomes. Interestingly,whenwemeasured the protein
level of oneof themost signiﬁcantly differentially expressed gene in
FHH males, ribosomal protein L36a,we found that only at 2 weeks
of age did the change in gene expression correlate with a change
in protein expression. This is in contrast to the ribosomal protein
L36a protein levels at 2 days, which show no increase despite a
substantial increase in ribosomal protein L36a gene expression at
that age in males. This discrepancy may be due to the ribosome
biogenesis machinery being saturated at 2 days of age and unable
to incorporate higher levels of ribosomal proteins. The tight regu-
lation of this biogenesis may likely be degrading excess ribosomal
proteins at the protein level or blocking translation of ribosomal
proteins at the mRNA level, although at present our data cannot
distinguish between these two possibilities. No change in riboso-
mal protein L36a protein expression was observed in FHH females
at 2 weeks of age, but this is not surprising given that no signiﬁ-
cant gene expression change of ribosomal protein L36a is seen in
these animals. However, given the following data, it is likely that
there is a reduction of one or more key ribosomal proteins at the
protein level in FHH females at 2 weeks. Conceivably by the time
the FHH rat has reached adulthood the kidney cells have adjusted
the half-lives and/or degradation rates of certain ribosomal pro-
teins in order to reach the normal number of mature ribosome
structures.
The most signiﬁcant ﬁnding of this study was that at 2 weeks
after birth, i.e., at the end of nephrogenesis (Marquez et al., 2002),
perinatalNOadministration resulted in a global reduction of ribo-
some structures in bothmale and female FHH rats.All of the peaks
representing major ribosome structures were found to be sub-
stantially decreased in molsidomine-treated FHH rats at 2 weeks
of age. This global reduction in NO-treated females at 2 weeks
was surprising because only two ribosomal protein genes, cod-
ing for ribosomal protein L16 and ribosomal protein L21, were
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FIGURE 4 | Polysome profiles of kidneys. Kidneys from control 2 day old
(males n=5, females n=6), 2week old (n=8 in both genders), and adult
(n=4 in both genders) and molsidomine-treated 2 day old (males n=4,
females n=6), 2week old (n=9 in both genders) and adult (n=5 in both
genders) FHH rats were proﬁled to measure the total number of assembled
ribosome structures. The peaks of 40S, 60S, and 80S were normalized against
the left-most peak and the results shown in the corresponding histograms.
#P <0.01 vs. untreated of the same peak.
signiﬁcantly reduced. Ribosomal protein L16 gene expression was
not reduced by molsidomine in FHH males at 2 weeks, but strik-
ingly 6 out of the 45 genes that were signiﬁcantly reduced coded for
ribosomal protein L21. This suggests that ribosomal protein L21
may be a key ribosomal protein in the biogenesis of the 60S large
subunit and may also play an unappreciated role in the biogenesis
of the 40S subunit. Additionally, ribosomal protein L21 appears to
be important in the development of craniofacial organs (Xie et al.,
2009) and a missense mutation in L21 leads to hereditary hypotri-
chosis simplex in humans (Zhou et al., 2011). Our ﬁndings suggest
that ribosomal protein L21 may have an as yet unrecognized role
in the development of blood pressure control mechanisms of the
kidney.
To our knowledge, this is the one of the most striking examples
of a drug-induced decrease in ribosome biogenesis in an animal
model to date that is not accompanied by deleterious effects. For
example, rapamycin, a powerful inhibitor of the mTOR path-
way that directly regulates ribosome biogenesis, when injected
into rats had only a slight effect on polysome proﬁles of liver
tissue (Reiter et al., 2004). However, doses of rapamycin as low
as 1 ng/mL have been shown to negatively affect cell function
and contribute to cell death, for instance in rodent islet cells
(Bell et al., 2003; Tanemura et al., 2009). Moreover, many verte-
brate and invertebrate models of deﬁciency of a single ribosomal
protein due to gene deletion, knockdown, or missense muta-
tions often show severe phenotypes (Caldarola et al., 2009), and
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FIGURE 5 | Polysome profiles of livers. Livers from 2-week-old FHH
males were proﬁled to measure the total number of assembled ribosome
structures. The peaks of 40S, 60S, and 80S were normalized against the
left-most peak and the results shown in the corresponding histograms.
Black and gray lines are from the control and molsidomine groups,
respectively.
models of biallelic loss of every ribosomal protein gene (with the
one exception of ribosomal protein L22; Anderson et al., 2007)
results in lethality. In contrast, our data suggest that a decrease
of ribosome biogenesis during a critical period of nephrogenesis
results in permanent physiologic changes to the kidney, which in
turn ameliorate the hypertension phenotype late in life. Inter-
estingly, the effects of exogenous NO on ribosomal biogenesis
did not affect the liver, underlining the crucial role of NO in
the developing cardiovascular system (Bustamante et al., 1996).
An obvious change linked to a decrease in ribosome biogenesis
would be a reduction in proliferation. However, immunohisto-
chemistry did not reveal a change in proliferation. Note that
although SIN-1, the active metabolite of molsidomine, can gen-
erate peroxynitrite in vitro, it appears to function solely as a
NO-donor at in vivo oxygen concentrations (Singh et al., 1999).
Indeed, recently we supplemented molsidomine to rescue cardiac
function in rats with cardiorenal failure and found no increase
in 3-nitrotyrosine in heart, kidney, or liver (Bongartz et al.,
2010).
The mechanism of action of NO administered perinatally to
FHH rats on ribosomal protein gene expression and the subse-
quent reduction of ribosome structures remains unclear. Indeed,
direct measurement of whole kidney NO content at 2 weeks failed
to show any effect of maternal NO-donor treatment, suggesting
that the decrease in ribosome biogenesis at 2 weeks is programmed
by an earlier event. Possibly maternal molsidomine intake results
in increased placental transfer of NO adducts and increased fetal
renal NO content. Alternatively, indirect effects on the placental
circulation could play a role. Indeed, although previous studies
(Cai et al., 2000) suggest a link between NO, rRNA synthesis and
proliferation, we were unable to establish any differences in pre-
rRNA levels in our model that would support direct effects of
exogenous NO on rRNA production (Figure A2 in Appendix).
This suggests that the effect of NOat 2 weeksmore likely lieswithin
epigenetically programmed transcriptional changes of ribosomal
FIGURE 6 | Phospho-histone H3 (pH3) immunohistochemistry.
Histology was performed on the kidneys from 2day, 2week and adult
control and molsidomine FHH rats of both genders for pH3. An example of
positive staining for pH3 in 2 day female molsidomine-treated FHH rat is
shown in (A). Several arrows indicate cells in mitosis staining positive for
pH3. The number of positive cells at 2 days and 2weeks is shown in (B).
Note that data in adults is not shown as all stained sections were
completely negative for pH3.
protein genes, as demonstrated by themicroarray results.Note that
in a previous study we did ﬁnd an increase in offspring kidney NO
content when spontaneously hypertensive rat (SHR) dams were
treated with citrulline (Koeners et al., 2007). Subsequently sib-
lings of these SHR had a lower blood pressure than control SHR.
The results of the present study suggest that mechanisms underly-
ing the antihypertensive effects of perinatal administration of the
NO-donor molsidomine in rats with genetic hypertension could
be quite different.
It has been previously established that perinatal NO adminis-
tration alleviates the hypertension phenotype in FHH rats (Koen-
ers et al., 2008b). Thepresent study suggests a potentialmechanism
underlying this phenotype alleviation. At this stage we have no
direct proof that the remarkable ribosomal changes we observe
provide the causalmechanism for the beneﬁcial effects of maternal
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NO on the blood pressure and renal function of the offspring.
However, our data demonstrate a novel possibility that long-term
amelioration of hypertension by NO in gestation may induce epi-
genetic changes that affect the postnatal transcriptionof ribosomal
protein genes and a reduction of ribosome structures during a
critical period of nephrogenesis.
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APPENDIX
METHODOLOGY MICROARRAY
After the hybridization of the samples to Illumina BeadChips
RatRef-12 the raw data set containing all probes of each BeadArray
was received. Each sample consisted of approximately 1 million
beads, interrogating about 23K unique probes encoding genes
(n = 22523), controls, housekeeping genes, and negative controls
(n = 825). Each gene is probed with at least 30 beads. Before aver-
aging the intensities of beads per probe, the outliers were removed,
using the same approach to removing outliers as in BeadStu-
dio. The removal of outliers was based on median ± 3× median
absolute deviation (MAD) and all beads with intensities outside
the area of median ± 3× MAD were removed. Outliers were fre-
quent for each probe. In our hands close to 90% of the probes
had outliers. Note that the outliers in “empty” beads, the negative
controls (NC), were not removed, as they were considered to be
background noise of the beads themselves. After removal of out-
liers (average 3 beads) the number of beads per probe averaged
39 beads.
After the test, the intensities of beads per probe are averaged
for further data processing. Before the normalization procedure,
the signiﬁcance of a call from a gene was detected by applying a
detection score that is dependent on the distribution of the inten-
sities and the average intensity of the gene and NC (regardless of
the number of NC). In this framework we performed the appro-
priate Student’s t -test between the beads of a gene and the average
intensity of all NC on the same array including testing (in)equality
between two population variances in order to enhance reliability
of the t -test. All probes with a signiﬁcant call above the negative
background were considered biologically active in the respective
sample.
The software (T4Illumina) was written to process the raw data
by averaging the intensities and determining the call of a gene,
including determining the (un)equality of variance and many
more. This software is available at request.
The signiﬁcance of the presence of a gene in a group of
samples (Figure A1) is outside the scope of the present study
and will not be handled in this document. Note that all genes
presented in the present study are signiﬁcantly biologically
active.
The averaged intensities, after removal of outliers, of the
probes from all BeadArrays are Log2-transformed and quan-
tile normalized. Next the arrays were grouped accordingly
and the average intensity per group was calculated. Finally
the signiﬁcance of the differences in intensities between
the groups was calculated using Cyber t -test. Cyber-T is a
statistics program designed speciﬁcally for microarray data
(http://cybert.ics.uci.edu/). Thenormalization,averaging,and sta-
tistics procedures can all be performed by the software Flex-
Array (http://gqinnovationcenter.com/services/bioinformatics/
ﬂexarray/index.aspx?l=e).
NORTHERN BLOT
Total RNA was isolated from kidneys using Trizol using the proce-
dure as recommended by the supplier (Invitrogen). Five micro-
gram of RNA was run on a formaldehyde 1% agarose gel in
MOPS buffer and DEPC-treated water for 4 h at 50V. The gel was
soaked in 50 mM NaOH for 15 min followed by 5 min in DEPC-
treated water followed by 30 min in 10× SSC buffer. The RNA was
transferred to a positively charged nylon membrane (GE Health-
care) overnight by capillary action and bound to the membrane
by UV-crosslinking at 120 mJ. The blots were hybridized with
DNAprobes overnight in ExpressHybHybridizationBuffer (Clon-
tech) at 65˚C. ETS and ITS1 DNA probes were made using the
following primers: ETS FW: 5′-GTCTCGGTACGGGTGTGTC-
3′ and REV 5′-TTTTTCCCCTTCCTCCTTTC-3′; ITS1 FW 5′-
GGCCTGTGTGAGTGTTCCTC-3′ andREV5′-TCAAGGGAAGA
GCGAGAAAA-3′. Probes were labeled with 32P-αCTP (Perkin-
Elmer) using a random primer DNA labeling system (Invit-
rogen). Following hybridization, blots were washed twice
for 30 min with 0.1% SDS/0.2× SSC at 65˚C. Blots were
exposed on storage phosphorimaging screens (Molecular Dynam-
ics) overnight and scanned using a Typhoon Scanner (GE
Healthcare).
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Table A1 | Collection of the top 20 strongest up- and down-regulated genes at all ages in each gender.
Entrez gene ID Symbol Definition Gene expression
2 Days 2Weeks Adult
A:TOP 40 OF MALE FHH OF 2 DAYS OLD (20 INDUCEDAND 20 REDUCED)
366411 RGD1560729 Ribosomal protein S24 0.820 −0.217 −0.354
500817 RGD1563124 40S ribosomal protein S20 0.723 −0.317 −0.409
287029 RGD1562055 Ribosomal protein L31 0.709 −0.399 −0.642
501876 RGD1563431 Large subunit ribosomal protein L36a 0.680 −0.424 −0.383
499560 LOC499560 LRRG00135 0.657 0.049 0.185
289384 RGD1560186 Ribosomal protein L37 0.632 −0.192 −0.844
500451 RGD1562259 40S ribosomal protein S20 0.534 −0.114 −0.452
362896 Stat6 Signal transducer and activator of transcription 6 (predicted),
transcript variant 1
0.526 −0.221 −0.058
501562 LOC501562 ORF2 consensus sequence encoding endonuclease and
reverse transcriptase minus RNaseH
0.514 0.009 0.181
171069 Usmg5 Upregulated during skeletal muscle growth 5 0.508 −0.372 −0.651
367923 LOC367923 60S ribosomal protein L23a 0.503 −0.394 −0.403
362894 RGD1310066 mKIAA1002 protein 0.493 0.214 0.146
314434 RGD1559566 60S ribosomal protein L9 0.488 −0.436 −0.369
291075 Peci Peroxisomal delta3, delta2-enoyl-coenzyme A isomerase 0.487 −0.242 0.313
680294 LOC680294 Ribosomal protein L19 0.485 −0.312 −0.510
315338 Hoxc10 Homeo box C10 0.480 −0.137 −0.223
500438 LOC500438 ORF2 consensus sequence encoding endonuclease and
reverse transcriptase minus RNaseH
0.478 −0.083 0.026
500923 RGD1565798 Tumor protein, translationally controlled 1 0.478 0.030 −0.106
301434 Clk1 CDC-like kinase 1 0.474 0.081 0.282
502887 RGD1563551 Ribosomal protein L31 0.470 −0.397 −0.523
287422 Per1 Period homolog 1 (Drosophila) −0.401 0.432 0.824
304063 Ets2 mapped v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) −0.415 0.104 −0.062
25458 Gss Glutathione synthetase −0.415 0.134 0.320
116546 Ralb v-ral simian leukemia viral oncogene homolog B (ras related) −0.417 −0.007 0.090
25122 Scnn1a Sodium channel, non-voltage-gated, type I, alpha −0.417 0.218 0.337
64017 Enpep Glutamyl aminopeptidase −0.422 0.102 0.787
29144 Canx Calnexin −0.431 0.298 0.689
24244 Calm3 Calmodulin 3 −0.443 0.037 0.067
500300 LOC500300 Hypothetical protein MGC6835 −0.446 0.090 1.036
290551 Chdh Choline dehydrogenase −0.456 0.256 −0.028
291081 RGD1309427 Tubulin, beta-like −0.462 0.018 −0.344
29517 Sgk Serum/glucocorticoid regulated kinase −0.466 0.661 0.862
294313 Mtch1 Mitochondrial carrier homolog 1 (C. elegans) −0.503 −0.072 −0.138
498290 RGD1561353 OTTHUMP00000044730 −0.506 0.040 0.267
25365 Actg2 Actin, gamma 2, smooth muscle, enteric −0.560 0.018 0.079
117273 Rhoa ras homolog gene family, member A −0.572 −0.047 −0.171
501211 LOC501211 LOC501211 −0.608 0.074 −0.596
287571 Taf15 TAF15 RNA polymerase II, TATA box binding protein
(TBP)-associated factor
−0.712 0.255 0.049
25279 Cyp24a1 Cytochrome P450, subfamily 24 −0.849 0.342 −0.634
25633 Dnase1 Deoxyribonuclease I −0.861 0.298 0.233
B:TOP 40 OF MALE FHH OF 2WEEKS OLD (20 INDUCEDAND 20 REDUCED)
498789 RGD1564865 20-alpha-hydroxysteroid dehydrogenase 0.056 0.685 −0.110
29517 Sgk Serum/glucocorticoid regulated kinase −0.466 0.661 0.862
81676 Hnmt Histamine N -methyltransferase 0.028 0.625 1.057
25526 Ptgds Prostaglandin D2 synthase (brain) −0.089 0.586 −0.559
362188 RGD1311652 MGC52019 protein 0.149 0.584 0.291
(Continued)
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Table A1 | (Continued)
Entrez gene ID Symbol Definition Gene expression
2Days 2Weeks Adult
83810 Trpv1 Transient receptor potential cation channel, subfamily V,
member 1
0.022 0.583 −0.373
246234 Slc34a3 Solute carrier family 34 (sodium phosphate), member 3 −0.149 0.559 −0.108
171072 Sult1c2 Sulfotransferase family, cytosolic, 1C, member 2 0.326 0.513 0.662
57300 Aadac Arylacetamide deacetylase (esterase) −0.051 0.508 0.040
25256 Fmo1 Flavin containing monooxygenase 1 0.092 0.506 0.044
363227 Obfc2a Oligonucleotide/oligosaccharide-binding fold containing 2A 0.145 0.452 −0.222
79428 Luzp1 Leucine zipper protein 1 −0.086 0.443 0.119
287422 Per1 Period homolog 1 −0.401 0.432 0.824
362216 Mrps26 Mitochondrial ribosomal protein S26 −0.154 0.427 −0.330
311826 Rexo4 REX4, RNA exonuclease 4 homolog (S. cerevisiae) −0.083 0.421 0.125
299944 RGD1304605 Hypothetical LOC299944 0.126 0.406 0.477
303926 Igsf11 Immunoglobulin superfamily, member 11 0.187 0.403 0.059
293343 MGC94288 4632419K20Rik protein −0.167 0.401 0.274
24267 Comt Catechol-O-methyltransferase −0.156 0.397 −0.180
81641 Anpep Alanyl (membrane) aminopeptidase 0.007 0.395 0.083
364108 RGD1562073 Ribosomal protein S17 0.418 −0.517 −0.490
29258 Rps7 Ribosomal protein S7 −0.076 −0.520 −0.650
60414 Rhd Rh blood group, D antigen 0.076 −0.521 0.066
494500 Yc2 Glutathione S-transferaseYc2 subunit 0.390 −0.550 −0.078
25748 Alas2 Aminolevulinic acid synthase 2, erythroid 0.021 −0.569 0.078
24615 S100a4 S100 calcium-binding protein A4 −0.090 −0.573 −0.730
300024 LOC300024 Ly6-B antigen gene −0.202 −0.575 −0.118
500988 RGD1564560 RCK −0.111 −0.623 0.905
500019 RGD1564980 60S ribosomal protein L29 (P23) −0.300 −0.666 −0.375
25250 Cox8h Cytochrome c oxidase subunit VIII-H (heart/muscle) −0.037 −0.689 0.061
54249 Cfd Complement factor D (adipsin) 0.001 −0.702 −0.297
361619 MGC72973 Beta-glo −0.232 −0.747 −0.638
291541 Cidea Cell death-inducing DNA fragmentation factor, alpha
subunit-like effector A
−0.234 −0.797 0.132
25357 Thrsp Thyroid hormone responsive protein 0.132 −0.829 0.021
293522 Eraf Erythroid associated factor −0.189 −0.834 −0.170
54232 Ca3 Carbonic anhydrase 3 −0.249 −0.867 −0.830
25475 Lgals5 Lectin, galactose binding, soluble 5 −0.218 −0.918 −0.225
81639 Alox15 Arachidonate 15-lipoxygenase −0.010 −1.005 0.035
79451 Fabp4 Fatty acid binding protein 4, adipocyte −0.189 −1.067 −0.061
24860 Ucp1 Uncoupling protein 1 (mitochondrial, proton carrier) −0.083 −1.330 0.041
C:TOP 40 OFADULT MALE FHH (20 INDUCEDAND 20 REDUCED)
117556 Sv2b Synaptic vesicle glycoprotein 2b 0.046 −0.471 1.766
313089 Slc7a13 Solute carrier family 7 (cationic amino acid transporter,
y+ system) member 13
0.150 0.029 1.419
498211 RGD1560523 S-adenosylmethionine synthetase gamma form (methionine
adenosyltransferase)
−0.037 0.124 1.251
50672 Ednrb Endothelin receptor type B 0.223 −0.396 1.238
117560 Klf9 Kruppel-like factor 9 −0.138 −0.059 1.220
501085 LOC501085 Sulfotransferase K1 −0.087 0.290 1.181
497772 LOC497772 Hypothetical gene supported by NM_030827 0.183 0.259 1.178
501610 LOC501610 Gag-Pol polyprotein 0.023 0.099 1.123
316256 Tnfrsf21 Tumor necrosis factor receptor superfamily, member 21 −0.013 0.252 1.112
367201 RGD1562392 Sulfotransferase K1 (rSULT1C2) 0.007 0.136 1.109
(Continued)
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Table A1 | (Continued)
Entrez gene ID Symbol Definition Gene expression
2 Days 2Weeks Adult
500621 LOC500621 Hydroxyacyl-Coenzyme A
dehydrogenase/3-ketoacyl-coenzyme A thiolase
−0.238 0.034 1.104
313729 Errﬁ1 ERBB receptor feedback inhibitor 1 0.002 0.084 1.091
310395 LOC310395 Nocturnin (CCR4 protein homolog) −0.232 0.105 1.074
361272 Dhtkd1 Dehydrogenase E1 and transketolase domain-containing 1 0.066 0.126 1.060
81676 Hnmt Histamine N -methyltransferase 0.028 0.625 1.057
364773 LOC364773 Liver regeneration-related protein LRRG07 −0.370 −0.192 1.043
500300 LOC500300 Hypothetical protein MGC6835 −0.446 0.090 1.036
24861 Ugt1a1 UDP glycosyltransferase 1 family, polypeptide A1 0.246 0.091 1.027
171361 Eef1a1 Eukaryotic translation elongation factor 1 alpha 1 0.101 −0.260 1.007
301276 RGD1564912 Mut protein −0.090 0.083 0.999
500180 LOC500180 IG kappa-chain V–V region K2 precursor 0.002 0.024 −0.796
502302 LOC502302 40S ribosomal protein S19 0.002 −0.034 −0.796
29191 Tac2 Tachykinin 2 −0.008 0.014 −0.805
362506 Ccl19 Chemokine (C–C motif) ligand 19 0.043 −0.170 −0.812
363074 RGD1309779 ENSANGP00000021391 −0.061 −0.042 −0.815
499300 Ptprcap Protein tyrosine phosphatase, receptor type, C
polypeptide-associated protein
0.009 −0.007 −0.817
361537 Tyrobp Tyro protein tyrosine kinase binding protein 0.030 −0.129 −0.824
54232 Ca3 Carbonic anhydrase 3 −0.249 −0.867 −0.830
299269 isg12(b) Putative ISG12(b) protein −0.072 −0.169 −0.833
292654 RGD1564549 Hypothetical protein FLJ20512 −0.173 0.064 −0.840
289384 RGD1560186 Ribosomal protein L37 0.632 −0.192 −0.844
360918 Pf4 Platelet factor 4 0.106 −0.299 −0.845
498744 RGD1561310 Ribosomal protein L37 0.151 −0.454 −0.851
367077 RGD1562835 40S ribosomal protein S26 0.170 −0.348 −0.852
24440 Hbb Hemoglobin beta chain complex −0.237 −0.127 −0.857
25632 Hba-a2 Hemoglobin alpha, adult chain 2 −0.105 −0.016 −0.860
299848 RGD1565117 40S ribosomal protein S26 0.029 −0.217 −0.882
499131 LOC499131 NADH:ubiquinone oxidoreductase B15 subunit −0.075 −0.156 −0.909
140608 Atp5i ATP synthase, H+ transporting, mitochondrial F0 complex,
subunit e
−0.139 −0.008 −0.971
692000 LOC692000 Dolichol-phosphate mannosyltransferase subunit 3 −0.190 0.095 −1.014
D:TOP 40 OF FEMALE FHH OF 2 DAYS OLD (20 INDUCEDAND 20 REDUCED)
499638 LOC499638 LRRGT00057 1.238 0.031 0.087
361117 LOC361117 LRRGT00149 1.206 −0.117 −0.136
500285 LOC500285 LRRGT00176 1.198 −0.039 0.029
498105 LOC498105 LRRGT00176 1.186 0.049 −0.044
498076 LOC498076 RIKEN cDNA 2410116I05 1.124 0.041 0.103
500586 LOC500586 LRRGT00057 1.110 −0.046 −0.062
498245 LOC498245 LRRGT00176 1.105 0.037 −0.039
313278 RGD1561090 Protein tyrosine phosphatase, receptor type, D 0.978 −0.065 0.104
362803 LOC362803 Putative RNA binding protein 1 0.888 0.045 −0.109
500380 LOC500380 LRRGT00008 0.885 0.117 −0.258
498623 LOC498623 LRRGT00176 0.844 0.044 −0.102
501156 LOC501156 LRRGT00176 0.793 0.074 −0.293
500988 RGD1564560 RCK 0.791 −0.432 −0.473
498979 LOC498979 LRRGT00194 0.763 0.035 −0.147
25365 Actg2 Actin, gamma 2, smooth muscle, enteric 0.752 −0.435 −0.126
309902 Cxxc6 CXXC ﬁnger 6 0.738 0.107 −0.008
(Continued)
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Table A1 | (Continued)
Entrez gene ID Symbol Definition Gene expression
2 Days 2Weeks Adult
500343 LOC500343 LRRGT00176 0.734 0.110 −0.138
315604 Ddx6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 0.597 −0.305 −0.006
498217 LOC498217 LRRG00135 0.595 0.063 −0.015
308831 Odz4 Odd Oz/ten-m homolog 4 (Drosophila) 0.595 −0.052 0.140
24832 Thy1 Thymus cell antigen 1, theta −0.336 −0.161 0.319
366942 RGD1565809 Ribosomal protein L15 −0.345 −0.070 0.010
362850 Angptl4 Angiopoietin-like 4 −0.352 −0.311 −0.221
25475 Lgals5 Lectin, galactose binding, soluble 5 −0.356 −0.162 0.207
64473 Bpnt1 Bisphosphate 3′-nucleotidase 1 −0.359 −0.134 0.009
338475 Nrep Neuronal regeneration-related protein −0.370 −0.154 0.300
294282 Rps18 Ribosomal protein S18 −0.377 −0.016 0.021
140582 Ddit4l DNA-damage-inducible transcript 4-like −0.389 −0.186 −0.055
360941 LOC360941 ORF7 −0.420 0.033 0.076
117273 Rhoa ras homolog gene family, member A −0.423 −0.239 −0.189
29222 Ptma Prothymosin alpha −0.426 −0.167 0.207
315745 Fem1b Feminization 1 homolog b (C. elegans) −0.448 −0.074 0.167
124440 Rpl 41 Ribosomal protein L41 −0.455 0.034 0.067
314397 Rin3 Ras and Rab interactor 3 −0.497 −0.156 −0.188
89813 Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 −0.498 −0.357 0.533
287571 Taf15 TAF15 RNA polymerase II, TATA box binding protein
(TBP)-associated factor
−0.503 −0.197 0.113
308568 RGD1309326 RIKEN cDNA 2410002F23 −0.539 −0.154 −0.089
246771 Slc25a25 Solute carrier family 25 (mitochondrial carrier, phosphate
carrier) member 25
−0.575 −0.393 −0.111
25633 Dnase1 Deoxyribonuclease I −0.588 −0.250 −0.274
360739 Ranbp1 RAN binding protein 1 −0.597 −0.306 0.453
E:TOP 40 OF FEMALE FHH OF 2WEEKS OLD (20 INDUCEDAND 20 REDUCED)
24567 Mt1a Metallothionein 1a −0.154 0.424 −0.075
64522 Slc5a2 Solute carrier family 5 (sodium/glucose cotransporter)
member 2
−0.110 0.419 −0.362
362334 Tmem140 Transmembrane protein 140 0.205 0.359 −0.333
313430 Fam151a Family with sequence similarity 151, member A −0.061 0.325 −0.358
360895 Rrp15 Ribosomal RNA processing 15 homolog (S. cerevisiae) 0.067 0.324 −0.001
362334 Tmem140 Transmembrane protein 140 0.207 0.284 0.051
289419 Nuak2 NUAK family, SNF1-like kinase, 2 0.037 0.278 −0.257
307098 Net1 Neuroepithelial cell transforming gene 1 −0.058 0.278 −0.049
24484 Igfbp3 Insulin-like growth factor binding protein 3 0.267 0.270 −0.206
303002 RGD1308952 mKIAA0665 protein 0.052 0.263 −0.163
85385 Shc1 src homology 2 domain-containing transforming protein C1 0.094 0.261 0.123
300659 Rnf26 Ring ﬁnger protein 26 −0.166 0.253 0.085
404871 Olr557 Olfactory receptor 557 (predicted) 0.023 0.251 −0.213
360228 LOC360228 WDNM1 homolog 0.257 0.248 −0.243
116565 Lrpap1 Low density lipoprotein receptor-related protein associated
protein 1
0.036 0.248 −0.180
25619 Plau Plasminogen activator, urokinase 0.225 0.242 −0.071
361367 Amfr Autocrine motility factor receptor 0.043 0.239 −0.135
171179 Keg1 Kidney expressed gene 1 0.014 0.238 −0.115
310810 Sdfr2 Stromal cell derived factor receptor 2 0.211 0.232 0.027
299027 Eif2s3x Eukaryotic translation initiation factor 2, subunit 3, structural
gene X-linked
−0.021 0.228 0.096
(Continued)
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Table A1 | (Continued)
Entrez gene ID Symbol Definition Gene expression
2 Days 2Weeks Adult
24856 Ttr Transthyretin 0.115 −0.331 0.062
309809 RGD1310495 KIAA1919 protein −0.028 −0.336 −0.184
311676 Tmepai Transmembrane, prostate androgen induced RNA 0.033 −0.340 0.199
89813 Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 −0.498 −0.357 0.533
246781 Ptpn7 Protein tyrosine phosphatase, non-receptor type 7 −0.008 −0.364 0.101
501194 LOC501194 Hypothetical protein D330021B20 0.249 −0.365 −0.110
291555 Atp8b1 ATPase, class I, type 8B, member 1 0.091 −0.392 −0.097
246771 Slc25a25 Solute carrier family 25 (mitochondrial carrier, phosphate
carrier) member 25
−0.575 −0.393 −0.111
303132 Aff4 AF4/FMR2 family, member 4 −0.014 −0.399 0.057
295660 RGD1564400 Eukaryotic translation initiation factor 5 −0.057 −0.407 −0.231
361296 Rnf125 Ring ﬁnger protein 125 0.270 −0.407 −0.134
64353 Pdlim5 PDZ and LIM domain 5 −0.063 −0.411 −0.297
25365 Actg2 Actin, gamma 2, smooth muscle, enteric 0.752 −0.435 −0.126
498859 LOC498859 LOC498859 −0.002 −0.449 −0.111
315190 Upk3a Uroplakin 3A 0.317 −0.459 −0.297
501530 LOC501530 LOC501530 0.442 −0.487 0.438
290704 LOC290704 Palladin 0.371 −0.516 −0.324
94197 Rab14 RAB14, member RAS oncogene family 0.122 −0.565 −0.194
25373 Ahsg Alpha-2-HS-glycoprotein 0.031 −0.711 0.092
498989 LOC498989 Ab2-143 0.646 −0.728 −0.269
F:TOP 40 OFADULT FEMALE FHH (20 INDUCEDAND 20 REDUCED)
361734 Ms4a4a Membrane-spanning 4-domains, subfamily A, member 4 −0.013 0.006 1.155
117518 Ccl17 Chemokine (C–C motif) ligand 17 −0.091 −0.034 1.052
406161 C4-2 Complement component 4, gene 2 0.048 0.197 0.885
304349 RGD1559588 Cell surface receptor FDFACT 0.010 −0.105 0.877
500172 LOC500172 Immunoglobulin kappa-chain 0.067 −0.083 0.871
29517 Sgk Serum/glucocorticoid regulated kinase 0.142 0.027 0.861
498982 RGD1560020 Myb proto-oncogene protein 0.143 0.078 0.801
298906 Pqlc3 PQ loop repeat containing 3 −0.044 −0.012 0.795
116676 Aldh1a2 Aldehyde dehydrogenase family 1, subfamily A2 0.216 0.134 0.790
64195 Mgl1 Macrophage galactose N -acetyl-galactosamine speciﬁc
lectin 1
−0.077 −0.030 0.769
29168 Ubd Ubiquitin D −0.115 0.087 0.754
313438 Dock11 Dedicator of cytokinesis 11 0.024 −0.113 0.727
681872 LOC681872 Interleukin 19 0.038 −0.033 0.726
246143 Nradd Neurotrophin receptor associated death domain −0.032 0.041 0.726
84032 Col3a1 Collagen, type III, alpha 1 0.057 −0.029 0.716
24366 Fgb Fibrinogen, B beta polypeptide 0.022 0.195 0.709
502902 RGD1565140 Clecsf12 protein −0.066 −0.009 0.692
501405 LOC501405 GTPase activating protein testicular GAP1 −0.015 −0.013 0.691
24251 Cd53 CD53 antigen 0.035 −0.049 0.681
298975 Scin Scinderin 0.095 0.095 0.679
309527 Ch25h Cholesterol 25−hydroxylase 0.055 −0.014 −0.713
286926 Tfpi2 Tissue factor pathway inhibitor 2 0.019 −0.005 −0.725
293538 RGD1565366 Hmx2 protein 0.256 −0.049 −0.737
24517 Junb Jun-B oncogene 0.116 −0.039 −0.745
24451 Hmox1 Heme oxygenase (decycling) 1 0.155 0.248 −0.771
292868 Klks3 Kallikrein, submaxillary gland S3 −0.113 −0.039 −0.771
(Continued)
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Table A1 | (Continued)
Entrez gene ID Symbol Definition Gene expression
2 Days 2Weeks Adult
363483 Dmrtc1c DMRT-like family C1c 0.096 0.076 −0.808
24498 Il6 Interleukin 6 0.055 −0.099 −0.826
78965 Csf1 Colony stimulating factor 1 (macrophage) 0.131 0.064 −0.837
24296 Cyp1a1 Cytochrome P450, family 1, subfamily a, polypeptide 1 0.102 −0.062 −0.857
24508 Irf1 Interferon regulatory factor 1 −0.214 0.033 −0.894
25542 Ccl3 Chemokine (C–C motif) ligand 3 0.102 0.064 −0.923
25464 Icam1 Intercellular adhesion molecule 1 −0.177 −0.058 −0.965
25361 Vcam1 Vascular cell adhesion molecule 1 0.133 −0.038 −1.099
362993 Rnd1 Rho family GTPase 1 0.054 −0.031 −1.161
24770 Ccl2 Chemokine (C–C motif) ligand 2 −0.007 −0.083 −1.232
116637 Ccl4 Chemokine (C–C motif) ligand 4 0.067 0.029 −1.322
114105 Cxcl2 Chemokine (C–X–C motif) ligand 2 −0.091 0.069 −1.504
25651 Selp Selectin, platelet −0.078 −0.032 −1.531
81503 Cxcl1 Chemokine (C–X–C motif) ligand 1 −0.075 −0.010 −2.156
The difference in gene expression between molsidomine-treated and control FHH was noted as Log2(FM/FC), where FM and FC are the normalized intensities. Red
and blue numbers indicate gene expression differentially induced and reduced by molsidomine, respectively.
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Table A2 | Ribosomal protein genes in kidneys of FHH males differentially expressed by molsidomine (FM, 2days and 2weeks) or after perinatal
molsidomine (FM, adult) vs. controls (FC).
Entrez gene ID Ribosome Chromosome Gene expression
2Days 2Weeks Adult
A: 2 DAYS
366411 S24 5 0.820 −0.217 −0.354
500817 S20 7 0.723 −0.317 −0.409
287029 L31 10 0.709 −0.399 −0.642
501876 L36a 13 0.680 −0.424 −0.383
289384 L37 13 0.632 −0.192 −0.844
500451 S20 5 0.534 −0.114 −0.452
367923 L23a 3 0.503 −0.394 −0.403
314434 L9 X 0.488 −0.436 −0.369
680294 L19 – 0.485 −0.312 −0.510
502887 L31 4 0.470 −0.397 −0.523
500322 S7 4 0.462 −0.192 −0.411
500510 L21 5 0.437 −0.044 −0.432
498078 L7a 11 0.427 −0.331 −0.354
364108 S17 14 0.418 −0.517 −0.490
294700 L21 2 0.409 −0.434 −0.293
287417 L26 10 0.399 −0.228 −0.253
295439 L21 2 0.353 −0.334 −0.175
314733 S19 7 0.329 −0.330 −0.638
289715 L37 14 0.314 −0.454 −0.554
364059 L34 13 0.299 −0.352 −0.662
365800 L36a 4 0.280 −0.014 −0.131
498828 L10 18 0.276 −0.241 −0.306
364825 L36 18 −0.199 0.117 0.126
B: 2WEEKS
362216 S26 3 −0.154 0.427 −0.330
308719 L27a 1 −0.068 0.243 0.044
503211 L21 8 −0.051 0.161 0.111
367030 SA 8 0.106 0.155 −0.061
287417 L26 10 0.399 −0.228 −0.253
298126 L31 5 0.018 −0.261 −0.566
313283 S12 5 0.045 −0.279 −0.548
287996 L21 11 −0.022 −0.281 0.002
296870 L34 X −0.008 −0.295 −0.283
364828 L29 18 0.132 −0.297 −0.506
500559 S20 5 0.132 −0.302 −0.188
498360 S23 14 0.033 −0.304 −0.164
680294 L19 – 0.485 −0.312 −0.510
500817 S20 7 0.723 −0.317 −0.409
367102 S9 8 −0.068 −0.325 −0.458
299935 L31 7 0.001 −0.328 −0.461
295439 L21 2 0.353 −0.334 −0.175
364059 L34 13 0.299 −0.352 −0.662
300731 L21 8 0.061 −0.352 −0.638
499133 L27a 1 0.119 −0.363 −0.477
687298 S19 10 0.059 −0.365 −0.541
366656 L10a 6 0.188 −0.370 −0.260
502854 L31 4 0.166 −0.376 −0.624
297755 L7 5 0.252 −0.386 −0.308
294781 L21 2 0.397 −0.388 −0.627
(Continued)
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Table A2 | (Continued)
Entrez gene ID Ribosome Chromosome Gene expression
2Days 2Weeks Adult
65139 S12 1 0.225 −0.393 −0.765
367923 L23a 3 0.503 −0.394 −0.403
287029 L31 10 0.709 −0.399 −0.642
501604 L7a X 0.287 −0.402 −0.218
81772 S9 1 0.252 −0.406 −0.620
289401 L31 13 0.243 −0.424 −0.735
501876 L36a 13 0.680 −0.424 −0.383
299740 L31 7 −0.024 −0.426 −0.539
294700 L21 2 0.409 −0.434 −0.293
314434 L9 X 0.488 −0.436 −0.369
300278 S9 X 0.414 −0.436 −0.590
289715 L37 14 0.314 −0.454 −0.554
498744 L37 17 0.151 −0.454 −0.851
501058 S23 8 0.054 −0.467 −0.297
363418 L17 12 0.068 −0.469 −0.316
81770 L37 2 −0.136 −0.472 −0.618
500817 S20 7 0.080 −0.484 −0.347
363861 L29 12 0.212 −0.490 −0.467
366887 L31 7 0.379 −0.497 −0.497
686564 L23a 14 0.520 −0.497 −0.446
364139 L21 14 0.150 −0.497 −0.758
364108 S17 14 0.418 −0.517 −0.490
29258 S7 5 −0.076 −0.520 −0.650
500019 L29 4 −0.300 −0.666 −0.375
C: 36WEEKS
360710 L7a 11 0.034 0.157 0.218
365300 L7 1 −0.007 0.004 −0.213
294282 S18 20 −0.094 −0.010 −0.337
498837 S27a 18 0.196 −0.043 −0.342
315521 L32 8 0.339 0.010 −0.363
367250 L7a 9 0.021 0.060 −0.371
365560 L36a 20 0.030 −0.097 −0.384
500451 S20 5 0.534 −0.114 −0.452
367102 S9 8 −0.068 −0.325 −0.458
299935 L31 7 0.001 −0.328 −0.461
499133 L27a 1 0.119 −0.363 −0.477
500559 S20 5 0.220 −0.339 −0.490
309408 S12 1 −0.079 −0.134 −0.495
498954 S16 19 0.099 −0.171 −0.499
302497 L10a X 0.334 −0.262 −0.499
25347 L39 X 0.014 −0.145 −0.512
302898 L1 10 0.034 0.076 −0.515
302528 L37a X 0.006 −0.041 −0.520
502887 L31 4 0.470 −0.397 −0.523
499752 L7a 3 0.115 −0.093 −0.527
124323 S23 2 0.163 −0.260 −0.529
293754 L16 1 −0.278 0.116 −0.548
313283 S12 5 0.045 −0.279 −0.548
289715 L37 14 0.314 −0.454 −0.554
315642 L27a 8 −0.162 −0.126 −0.560
298495 L35a 5 0.296 −0.332 −0.565
(Continued)
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Table A2 | (Continued)
Entrez gene ID Ribosome Chromosome Gene expression
2 Days 2Weeks Adult
298126 L31 5 0.018 −0.261 −0.566
366689 L21 6 −0.128 −0.317 −0.575
81768 L22 5 0.002 −0.148 −0.580
300278 S9 X 0.414 −0.436 −0.590
292539 L17 1 0.237 −0.246 −0.592
498363 P2 14 0.481 −0.130 −0.597
299041 P1 X 0.041 −0.157 −0.601
57809 L35a 1 −0.112 −0.210 −0.614
81772 S9 1 0.252 −0.406 −0.620
502854 L31 4 0.166 −0.376 −0.624
294781 L21 2 0.397 −0.388 −0.627
314054 S10 6 −0.053 −0.170 −0.631
314733 S19 7 0.329 −0.330 −0.638
287029 L31 10 0.709 −0.399 −0.642
498555 P2 15 0.002 −0.072 −0.645
503110 S19 7 0.008 −0.047 −0.651
64360 L23 1 −0.247 0.029 −0.654
297459 S25 4 −0.247 0.160 −0.659
314248 S17 6 0.000 −0.064 −0.661
364059 L34 13 0.299 −0.352 −0.662
171061 L17 1 0.219 −0.170 −0.663
366485 – 5 −0.275 −0.376 −0.665
500714 L6 6 0.023 −0.218 −0.686
289401 L31 13 0.243 −0.424 −0.735
27139 S26 7 0.205 −0.240 −0.760
65139 S12 1 0.225 −0.393 −0.765
498523 L23a 15 −0.134 −0.253 −0.766
289932 S7 15 0.098 −0.295 −0.785
502302 S19 1 0.002 −0.034 −0.796
289384 L37 13 0.632 −0.192 −0.844
498744 L37 17 0.151 −0.454 −0.851
367077 S26 8 0.170 −0.348 −0.852
299848 S26 7 0.029 −0.217 −0.882
All genes that are signiﬁcantly differentially expressed by molsidomine are arranged per age [(A) is newborn males, i.e., 2 days, (B) is 2-week-old males, and (C) is
adult males, i.e., 36weeks]. The difference in gene expression between molsidomine-treated and control FHH was noted as Log2(FM/FC), where FM and FC are
the normalized intensities. Red and blue numbers indicate gene expression differentially induced and reduced by molsidomine, respectively. The symbols and the
chromosomal locations are also shown. Ratios indicated in bold and red are increased differential expression and ratios indicated in bold and blue are decreased
differential expression. Note that some genes in (A) may reappear in (B,C) and some genes in Table A2B may reappear in Table A2C.
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FIGUREA1 |Total number of genes differentially expressed by
molsidomine at each age per gender. Hundreds of genes were
signiﬁcantly affected by molsidomine at each age in both genders. The
distribution of the genes over all ages is shown in a Venn diagram. The up
and down arrows indicate genes that are differentially induced or reduced by
molsidomine vs. control, respectively. Below the diagram are the total
numbers of genes that are differentially expressed by molsidomine vs.
control.
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FIGUREA2 | Northern Blots. Northern blotting was performed on kidneys
from 2week FHH in order to determine rates of pre-rRNA processing. ETS:
external transcribed spacer. ITS1: internal transcribed spacer 1. Ethidium
bromide (EtBr) is shown as loading control. Note the slight decrease of
molsidomine-treated males is due to loading (seen by EtBr) and not due to
processing defects of pre-rRNA.
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